Colon Cancer Drug Effective in MMR-mutant Cancer

Immunotherapy drug pembrolizumab used for colon cancer is effective against cancers with defect in a genome maintenance pathway called mismatch repair.

Particular genetic defects in tumors can be used as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade, finds a recent study.

Until recently, PD-1 blockade therapies have only been approved for a select few classes of cancers, such as colon cancer. Because clinical tests for the particular indicator defects are widely available, these results could establish a new standard of care to test for them in tumors.

Colorectal Cancer Screening
Colorectal screening is done using tests to detect blood in stool, colonoscopy or sigmoidoscopy ordouble contrast barium enema or CT colonography.

‘Immunotherapy might be useful for as many as 60,000 MMR-mutant cancer cases every year in the United States, based on analysis of genome sequencing data.’

It could also help identify those patients who might benefit from immunotherapy.

In an 86-participant clinical trial across 12 different types of cancer, Dung Le et al. found the immunotherapy pembrolizumab (an anti-PD-1 antibody) was actually effective against multiple forms of cancer. The drug controlled disease for 66 patients, and tumors completely disappeared in 18 people.

The responding tumors all had defects in a genome maintenance pathway called mismatch repair (MMR). PD-1 blockade therapies can unleash the immune system against aberrant proteins on the surface of malignant cells called neoantigens, which accumulate because some cancers have inherently unstable genomes.

Diet to Prevent Colon Cancer - Health Tips - Glossary
Diet and lifestyle play an important role in reducing the risk and delaying the onset of cancer. Incorporating and eliminating certain other foods may reduce the risk of acquiring colon cancer.

The researchers characterized neoantigens in biopsy sample responses from three responding patients to confirm that MMR-deficient cancers contained immune cells that can be let loose against tumors using PD-1 blockade.

The scientists determined that immunotherapy might be useful for as many as 60,000 MMR-mutant cancer cases every year in the United States, based on analysis of genome sequencing data from 12,019 cancers representing 32 distinct tumor types.

Health Screening for Men between 40 and 64 years of Age
Health screening in men between 40 and 64 years of age helps to detect illnesses and cancers when they can be controlled or treated before complications set in.

Though the trial is still ongoing, 11 patients were able to stop taking the therapy since beginning; they have remained disease-free with no evidence of recurrence for an average of 8.3 months.

Source-Eurekalert

Why is Health Screening in Women between 40 and 60 years of age important?
Health screening in women between 40 and 60 years helps to diagnose health issues in the early stages when they can be controlled. This ensures a more comfortable old age.